Esperion Therapeutics ESPR Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's additional paid-in capital?
- Esperion Therapeutics (ESPR) reported additional paid-in capital of $1.4B in Q1 2026.
- How has Esperion Therapeutics's additional paid-in capital changed year-over-year?
- Esperion Therapeutics's additional paid-in capital increased by 9.9% year-over-year, from $1.27B to $1.4B.
- What is the long-term trend for Esperion Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Esperion Therapeutics's additional paid-in capital has grown at a 11.5% compound annual growth rate (CAGR), from $797.66M to $1.38B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.